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Avian Influenza
Marcia L. Headrick, DVM, MPH
State Public Health Veterinarian
Division of Acute Disease Epidemiology
Some scientists say we are “overdue” for a human
influenza (flu) pandemic and that an avian virus could be
the cause.  For avian flu to cause a human pandemic, it
must be efficiently transmitted from person to person.
Currently, this is not the case.
However, we are concerned about a particular avian flu
virus that is circulating in birds in Asia, Europe, and more
recently in Africa.  There are many types of avian flu, but the
one we are concerned about is called highly pathogenic
H5N1 (named for its specific surface antigens).  Highly
pathogenic avian flu viruses cause high mortality in poultry,
such as chickens and turkeys.  Officials aren’t exactly sure
how it is spreading, but there are several theories.  The
H5N1 virus has been found in healthy migratory birds, so
some scientists believe the healthy birds are spreading it
as they migrate.  There is also direct evidence of legal and
illegal movements of infected birds and contaminated
poultry products through commerce as the source of
spread.  Whatever the source, the H5N1 virus is resulting
in a high level of concern on the part of agricultural officials
and the commercial poultry industry in the U.S.  Although
H5N1 has not been identified in the U.S., it could devastate
our poultry industry.  The federal government is
implementing surveillance plans for H5N1 through the
states.  The early detection system is focused on the U.S.
Migratory Bird Flyways, in particular, Alaska and the Pacific
Migratory Bird Flyway, as this area is a risk for introduction
of H5N1 into the U.S.  Poultry surveillance plans have also
been enhanced to sample commercial and backyard
poultry flocks.
Although we are not considered a high-risk area, South
Carolina is preparing for the possibility of H5N1 in our
wild birds or commercial poultry.  Although plans have not
been finalized, the state has drafted a working plan for
responding to a human pandemic flu. The draft is part of
the S.C. State Emergency Operations Plan.  In addition,
Clemson University Livestock Poultry Health (CULPH)
program and the S.C. poultry industry are working on plans
to prepare for avian flu in poultry.
(Portions of the following information
are excepts from a “Dear Colleague”
letter dated January 18, 2006, by John
Ward, MD, Director of the Division of
Viral Hepatitis at the Centers for
Disease Control and Prevention
(CDC) and Lance Rodewald, MD,
Director of the Division of
Immunization Services, National
Center for Infectious Diseases,
National Immunization Program,
CDC).
The Advisory Committee on
Immunization Practices (ACIP) has
revised the hepatitis B immunization
recommendations in order to ensure
that newborn infants are protected
from hepatitis B virus (HBV) infection,
a major cause of cirrhosis and liver
cancer in the United States.  In the
previous recommendations, the ACIP
noted a preference for giving the first
dose at birth to all infants, but stated
that infants born to uninfected mothers
could receive the first dose at age 1-2
months.  The ACIP now recommends
that, except on a case-by-case basis
and only in rare circumstances,
universa l  in fant  hepatitis B
vaccination should begin at birth.  To
prevent HBV transmission among
children at greatest risk for HBV
infection, the ACIP also recommends that prenatal care
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providers, delivery hospitals, and health departments
implement policies and procedures to identify and
manage children born to infected mothers and mothers
with unknown HBV infection status.
The ACIP statement, including all of the revised
recommendations, is available from the CDC in the
Morbidity and Mortality Weekly Report at (http://
www.cdc.gov/mmwr/PDF/rr/rr5416.pdf). A synopsis of the
updated ACIP recommendations is provided below.
Recommendations for Prenatal Care Providers
Management of All Pregnant Women
• Test all pregnant women for hepatitis B surface
antigen (HBsAg) during each pregnancy.
• Transfer a copy of the original laboratory report of
the pregnant woman’s HBsAg test result to the
patient’s medical record in the delivery hospital.
• Inform pregnant women of the importance of
newborn hepatitis B vaccination.
        • Vaccinate pregnant women who are at risk for
               HBV infection.
Management of Pregnant Women Who Are HBsAg
Positive
• Inform HBsAg-positive women of HBV
transmission risks and ways to prevent HBV
infection, including the importance of
postexposure prophylaxis for newborn infants and
hepatitis B vaccination of household, sexual, and
needle-sharing contacts.
• Refer HBsAg-positive women to an appropriate
case-management program to ensure that their
newborn infants receive timely postexposure
prophylaxis and follow-up.
• Provide or refer HBsAg-positive women for
appropriate medical management of their HBV
infection.
Recommendations for Delivery Hospitals
Management of All Newborns
        • Implement standing orders to ensure that, except
in rare circumstances (see ACIP statement in
MMWR for additional details), all medically stable
newborns with birth weights of  > 2,000 grams
receive hepatitis B vaccine before discharge.
Only single-antigen hepatitis B vaccine should
be used for the birth dose.
Management of Infants Born to HBsAg-Positive Mothers
and to Mothers With Unknown HBsAg Status
        • Implement policies and procedures to ensure
that all infants born to HBsAg-positive mothers
and all infants born to mothers with unknown
HBsAg status are identified and receive
appropriate immunoprophylaxis. These policies
and procedures should include the following
standing orders:
¾ Review HBsAg test results for all
pregnant women at the time of
admission for labor and delivery.
¾ Conduct HBsAg testing as soon as
possible after admission for pregnant
women who do not have a documented
HBsAg result and for pregnant women
identified as being at risk for HBV
infection during pregnancy (e.g., >1 sex
partner in the previous 6 months,
evaluation or treatment for a sexually
transmitted disease, recent or current
injection-drug use, HBsAg-positive sex
partner).
¾ Administer hepatitis B vaccine and
hepatitis B immune globulin within12
hours of birth to all infants born to HBsAg-
positive mothers.
¾ Administer hepatitis B vaccine within 12
hours of birth to all infants born to
mothers with unknown HBsAg status.
¾ Document on the infant’s medical record
the maternal HBsAg test results and the
infant’s hepatitis B immunization.
Recommendations for Health Departments
Case Management Services
         • Provide or assure case-management services
to ensure that:
  ¾ All pregnant women are tested for
HBsAg during each pregnancy.
        ¾ All HBsAg-positive pregnant women are
reported to the health department with
each pregnancy.
        ¾ Infants born to HBsAg-positive women
and to women with unknown HBsAg
status receive recommended
immunoprophylaxis and follow-up.
Before hepatitis B vaccination became routine in the United
States, transmission of HBV infection perinatally and
during early childhood caused an estimated 30%-40% of
chronic HBV infections. Approximately 25% of chronically
infected children die prematurely from cirrhosis or liver
cancer. The majority of chronically infected persons remain
asymptomatic until the onset of cirrhosis or end-stage liver
disease.
These recommendations update the ACIP strategy to
eliminate HBV transmission in the United States. This
strategy has been implemented with considerable
success and has resulted in a substantial decline in
hepatitis B incidence in the United States. However,
challenges remain to eliminate perinatal and childhood
HBV transmission. In particular, CDC estimates that only
about half of expected births to HBsAg-positive mothers
are identified for case management, which is needed to
maximize on-time delivery of postexposure
immunoprophylaxis. In addition, errors in management
of infants born to HBsAg-positive mothers and infants
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Immunization Requirements for Child
Day Care Facilities And Schools
Jesse Greene, MSN, RN, Director
DHEC Immunization Division
South Carolina laws1 and regulations2 ensure that most3
children are protected from vaccine-preventable diseases
(VPDs) upon entry into child care facilities and public and
private schools.  Since enactment in 1976 and amended
in 1993, these laws and regulations represent major
immunization milestones in the state, resulting in high
levels of immunization coverage among preschool-aged
children4.
An important characteristic of most vaccines is that they
provide both individual and community protection. Most
vaccine-preventable diseases are transmitted from person
to person. When a sufficiently large proportion of individuals
in a community are immunized, their collective immunity
provides a protective barrier against the potential
transmission of the disease. This indirectly protects people
in the community who are not immunized and those for
whom vaccine failures may have occurred. Increased rates
of immunization result in significantly decreased risk for
disease.
Currently, there are 18,607 students or 2.56 percent of all
students in South Carolina who have medical exemptions
to at least one required vaccine. Some of these medical
exemptions are temporary; the student will receive the
vaccine when the physician determines that the
contraindication no longer exists. Other medical
exemptions are permanent.  There are also 1,588 school
students or 0.22 percent of all students in South Carolina
who have religious exemptions to immunization.  Over the
past 10 years these immunization exemption proportions
have remained static.
While legislation to mandate particular vaccinations is
intended to protect both individuals and communities,
certain individuals remain susceptible to VPDs in all
grades and in all schools (Malone 2003).  That is why
schools and child care facilities are required to have on
file and on site either the S.C. Certificate of Immunization,
which includes medical exemptions, or the S.C. Certificate
of Religious Exemption. These readily accessible records
ensure that, should there be a VPD outbreak, DHEC will
be able to quickly identify unprotected children/students
and remove them from harm’s way.
Each year in January, DHEC publishes the Schedule of
Required Immunizations for School Admittance and the
Required Standards of Immunization for Day Care
Attendance.  These immunization requirements are mailed
to immunization providers and schools throughout the state
and are also posted on the following DHEC Web page:
http://www.scdhec.gov/health/disease/immunization/
immunizations.htm
2006-2007 SCHOOL YEAR SCHEDULE OF REQUIRED
VACCINATIONS, SCREENINGS, AND IMMUNIZATIONS
FOR SCHOOL ADMITTANCE
Pursuant to Regulation 61-8, the South Carolina
Department of Health and Environmental Control (DHEC)
has declared the schedule of required vaccinations,
screenings, and immunizations as listed below necessary
for a child to be admitted to any public, private, or parochial
school, grades five-year old kindergarten through grade
twelve (K-12) for the 2006-2007 school year.  Immunization
requirements for school admittance apply to all grades
(five-year-old kindergarten through grade 12) and begin
for children who have attained the age of five (5) years and
are attending five-year old kindergarten.  Immunization
requirements for day care attendance apply to all children
ages 3 months through five (5) years.  A five (5) year old
child not enrolled in five-year old kindergarten must meet
the day care attendance immunization requirements if
attending day care or a child development program under
the control of the State Department of Education.
born to mothers with unknown HBsAg status have kept
many of these infants from receiving appropriate
immunoprophylaxis to prevent HBV infection.
Additional resources may be found at the following
website:
http://www.cdc.gov/ncidod/diseases/hepatitis/b/acip.htm
DHEC’S Role in Prevention of Perinatal Hepatitis B:
• DHEC provides case management for all HBsAg-
positive mothers and their infants, including
mothers and infants who are receiving care from
their private health care provider.  Individual case
management ensures: 1) complete follow-up,
including reporting of HBsAg test results between
outpatient and hospital-based providers, 2) post-
exposure prophylaxis for infants of HBsAg-positive
women, 3) vaccine series completion, and 4)
post-vaccination testing of infants.
• DHEC provides vaccination services and post-
vaccination testing to infants of HBsAg-positive
mothers, and offers vaccination to household and
sexual contacts of HBsAg-positive pregnant
women.
• DHEC conducts surveillance for viral hepatitis,
including perinatal hepatitis B.
For questions, consultation, and reporting, please call
your local health department, the DHEC Immunization
Division in Columbia at 803-898-0460, or the DHEC Division
of Acute Disease Epidemiology in Columbia at 803-898-
0861. For reporting, a completed DHEC Disease Reporting
Card may also be sent to your local health department.
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Minimum Requirements
¾ Four (4) doses* of any combination of DTP, DT, DTP-
Hib, DTaP, or Td vaccine with at least one (1) dose
received on or after the fourth birthday.
*This immunization requirement only
applies to students entering five-year-old
kindergarten and first grade in school year
2006-2007.  Students previously enrolled
in grades 2 through 12 met the requirement
as stated for the school year in which they
entered school.
If the fourth dose of DTaP, DTP, or DT is
administered before the fourth birthday, a
booster dose is required at 4-6 years of
age.  The fifth dose is not required if the
fourth dose was given on or after the fourth
birthday.  The minimum interval between
DTaP dose #3 and #4 or #4 and #5 is six
months.
¾ Three (3) doses of any combination of oral or
inactivated Polio vaccine with at least one (1) dose
received on or after the fourth birthday.
¾ Two (2) doses of Rubeola (Measles) vaccine with both
doses received on or after the first birthday and
separated by at least one month.
¾ One (1) dose of Rubella (German Measles) vaccine
received on or after the first birthday.
¾ One (1) dose of Mumps vaccine received on or after
the first birthday.
¾ Three (3) doses of Hepatitis B vaccine.
¾ One (1) dose of Varicella vaccine received on or after
the first birthday or positive history of disease for all
children admitted to kindergarten, first, second, third,
fourth, fifth, and sixth grades.
2006 – 2007 SCHOOL YEAR
REQUIRED STANDARDS OF IMMUNIZATION
FOR DAY CARE ATTENDANCE
Minimum Immunization Requirements for Day Care
Attendance
Pursuant to Section 44-29-180 of South Carolina State
Law, children less than six years of age who attend a
licensed public or private child day care facility or a
registered church or religious child day care facility must
present to the day care facility a South Carolina Certificate
of Immunization (DHEC form 1148), which assures they
are “up-to-date” or “catching-up” on the childhood
immunizations recommended and routinely provided by
the South Carolina Department of Health and
Environmental Control (DHEC).
Minimum Immunization Requirements for the Final
Certificate for Day Care Attendance**
Also pursuant to Section 44-29-180 of South Carolina State
Law, DHEC has declared the following required standards
of immunization necessary for a child to receive the final
immunization certificate for day care attendance in South
Carolina:
¾ Four (4) doses of any combination of DTP, DT, DTP
        Hib, or DTaP vaccine.
¾ Three (3) doses of any combination of oral or
        inactivated Polio vaccine.
¾ Three (3) doses of Hepatitis B vaccine.
¾ Current, age-appropriate Haemophilus influenzae
type b conjugate vaccination according to the current
Recommended Childhood Immunization Schedule,
United States – approved by the ACIP, the AAP, and the
AAFP.
¾ One (1) dose of Rubeola (Measles) vaccine received
on or after the first birthday.
¾ One (1) dose of Rubella (German Measles) vaccine
received on or after the first birthday.
¾ One (1) dose of Mumps vaccine received on or after
        the first birthday.
¾ One (1) dose of Varicella (chickenpox) vaccine
        received on or after the first birthday.
            **Minimum requirements for a final certificate for
day care attendance should not be confused with
theRecommended Childhood and Adolescent
Immunization Schedule as published by the
Advisory Committee on Immunization Practices
(ACIP).
Reference:  Malone KM, Hinman AR. Vaccination Mandates:
The Public Health Imperative and Individual Rights.  In:
Goodman RA, Rothstein MA, Hoffman RE, et al., Eds. Law
in Public Health Practice.  New York: Oxford University
Press, 2003: 262-84.
11 §44-29-180 and § 44-29-190
2 Regulation 61-8
3 Percentage of children in child day care fully
immunized 95.9 percent; Percentage of all students
entering five-year old kindergarten fully immunized 98.8
percent.
4 DHEC Child Day Care Facility and School Annual
Audits
South Carolina Needs More Participation
in the Sentinel Influenza Surveillance
Providers Network
Lena Bretous, MD, MPH
Medical Epidemiologist
Division of Acute Disease Epidemiology
With increased attention on avian influena and the possible
development of novel influenza strains with pandemic
potential, year round surveillance is more important than
ever. South Carolina has been conducting year round
surveillance for the past two years.  The state currently
has 60 sentinel providers participating in the surveillance
network. Of those, however, only 62 percent report regularly.
In addition, participation in the network by upstate and low
   (Continued on Page 5)
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West Nile Virus in 2006-07 Season
Lena Bretous, MD, MPH
Medical Epidemiologist
Division of Acute Disease Epidemiology
Arboviral neuroinvasive disease is a state reportable
disease.  Patients suspected of having West Nile
neuroinvasive disease (encephalitis, meningitis, or
poliomyelitis) should be reported to the local public health
department.  Clinical specimens from these patients
should include either CSF or serum and be sent to the
DHEC bureau of laboratories for confirmation.
West Nile neuroinvasive disease (WNND) diagnosis
requires both neuroinvasive symptoms and laboratory
evidence of West Nile Virus (WNV), in the absence of a
more likely clinical explanation.  Acute and convalescent
specimen testing is ideal.
With warm spring weather comes mosquitoes and the
need for the public to reduce their risk of exposure to West
Nile virus-infected mosquito bites.   Risk reducing activities
include:
• Limiting outdoor activity during peak mosquito
activity hours of dawn and dusk.
• Use of insect repellent containing DEET when
outdoors.
• Keeping window and door screens intact.
DHEC began accepting dead blue jays and crows for WNV
testing on March 15, 2006.  For more clinical information
on WNV disease, please visit the following CDC Web site:
http://www.cdc.gov/ncidod/dvbid/westnile/index.htm
(INFLUENZA SURVEILLANCE cont'd from Page 4)
country providers is minimal. Effective use of the
surveillance network requires participation from providers
in all areas of the state.
Each week, the sentinel providers report the total number
of patients seen and the number of patients with influenza-
like illness (ILI) by age group.  For this system, ILI is defined
as fever (temperature of >100°F) plus either a cough or a
sore throat.  Patients are not required to have had a
laboratory test to be considered an ILI case.
The Centers for Disease Control and Prevention (CDC) is
encouraging continued vigilance for early detection of avian
influenza cases in the U.S. The CDC is urging year round
participation by sentinel influenza surveillance providers
and attention to travel history in patients with upper
respiratory symptoms and fever.
To participate in the Sentinel Influenza Surveillance Provider
(ILI) Network, please contact your local public health
department.  The DHEC Influenza Information Web site is
updated weekly to reflect sentinel surveillance as well
asrapid influenza and influenza culture activity by county in
the state.  The DHEC Influenza Web address is:
http://www.scdhec.gov/health/disease/acute/flu.htm.
(AVIAN INFLUENZA cont'd from Page 1)
CULPH has been performing routine avian influenza
surveillance on poultry for more than 15 years, including
using recently acquired molecular detection techniques.
Tabletop exercises and testing of emergency
preparedness equipment have been conducted, and
additional incident command structure training and
exercises are scheduled.  CULPH personnel are prepared
to respond to an outbreak of avian flu in a poultry flock.
The following CULPH Web site includes a detailed power
point presentation describing South Carolina’s
preparedness efforts and information on avian flu:
http://www.clemson.edu/LPH/animaldisease
information.htm#Poultry
South Carolina is also working with the federal government
to prepare all our citizens, including health care providers,
businesses, faith-based communities, and other groups,
for a possible future flu pandemic.  A meeting was held on
March 2, 2006 in Columbia to “jump start” those efforts.
Additional information on the flu, and avian flu in particular,
can be found at the following Web sites:
• DHEC: http://www.scdhec.gov
• Centers for Disease Control (CDC): http://
www.cdc.gov/flu/avian/outbreaks/current.htm
• ProMed Digest: http://www.promedmail.org
• Food and Agriculture Organization (FAO): http://
www.fao.org/ag/againfo/subjects/en/health/
diseases-cards/special_avian.html
• World Health Organization (WHO): http://
www.who.int/csr/disease/avian_influenza/en/
• USDA Animal and Plant Health Inspection Service
(APHIS): http://www.aphis.usda.gov/vs/ceah/ncahs/
nsu/outlook
Ciguatera Fish Poisoning from Fish
Caught off the Coast of South Carolina
Mary Anne Wenck, DVM, MPH
Epidemic Intelligence Service Officer
Charles J. Moore, Maine Resources Division,
South Carolina Department of Natural Resources
Ciguatera fish poisoning is caused by toxins produced by
the dinoflagellate Gambierdiscus toxicus, which grows
worldwide in tropical areas and serves as food for
herbiverous fish. The toxins, which are lipid-soluble,
bioaccumulate so that levels are highest in large predatory
fish such as the barracuda, grouper, and snapper. The
toxins are heat-stable, so cooking the fish does not render
it safe to eat. The range of fish containing the ciguatera
toxin appears to be spreading; one barracuda caught off
the coast of Charleston in 2004, which caused ciguatera
fish poisoning in two people who consumed it, tested
positive for Caribbean ciguatoxin. This was the first
documented case of a ciguatera-contaminated fish caught
from the Atlantic coast north of Florida. There have also
been reports of suspected cases of ciguatera fish
   (Continued on Page 8)
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Time to Order Influenza Vaccine for the 2006-07 Season
Linda Kelly, Vaccine Manager
DHEC Immunization Division
Jesse Greene, MSN, RN, Director
DHEC Immunization Division
The four manufacturers of influenza vaccine for the 2006-07 season are listed below with contact information.
Prebooking of vaccine orders should be placed now for the upcoming season.  DHEC strongly recommends that
providers place orders for vaccine now to help insure an adequate supply for their high-risk patients in the
upcoming influenza season.
Manufacture                             Distributor                                Contact
Chiron Vaccines Chiron 1-800-244-7668
GlaxoSmithKline GlaxoSmithKline 1-866-475-8222
MedImmune MedImmune 1-877- FLUMIST
Sanofi pasteur Sanofi pasteur 1-800-VACCINE
Unfortunately, neither the Centers for Disease Control (CDC) nor the South Carolina Department of Health and
Environmental Control (DHEC) controls the distribution of flu vaccine outside of the programs that they operate.
CDC operates a flu vaccine program for children that DHEC helps to administer. In addition, DHEC operates a flu
vaccine program, primarily for older adults, through each county health department.  Most of the flu vaccine used
in South Carolina is through doctors’ offices and hospitals.
This year and in years past, distribution of flu vaccine has created problems.  The manufacturers who make the
vaccine take orders for the vaccine from all providers, doctors’ offices, hospitals, public health agencies – including
CDC, and pharmacies.  Some pharmacies supply doctors’ offices, hospitals, and nursing homes, while other
pharmacies supply drugstore-sponsored flu shot clinics.
In most cases, the flu vaccine manufacturers or their distributors deliver flu vaccine to whomever ordered it first,
despite requests from CDC for distributors to supply public health agencies and doctors’ offices first.  DHEC
usually places a flu vaccine order each February for the coming fall flu shot season.  CDC and DHEC have gone
on record with the U.S. Congress to encourage improvements in the mal-distribution of flu vaccine from the
companies that are responsible for distribution.   DHEC continues to advocate that the best place to receive a flu
shot is in the doctor’s office.
The increased interest in getting a flu shot is helping to increase the amount of influenza vaccine produced by
manufacturers.  With increased availability of vaccine supplies, distribution problems generally diminish.  However,
the entire supply takes time to distribute.  Furthermore, vaccine must be used because supplies unused become
disincentives for increased production.
An unpredictable supply of influenza vaccine is a major pandemic influenza public health preparedness planning
challenge, as is increasing the nation’s influenza vaccine production capacity.  Thus, a core element of pandemic
preparedness planning is to increase influenza vaccine uptake, therefore resulting in an increase in vaccine
production.
There is room for improvement in vaccinating South Carolina’s population against influenza.  Everyone working to
improve influenza vaccination coverage should order flu vaccine now.
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School and Childcare Exclusion Lists
Michelle Myer, MSN, RN, CPNP
Epidemiology and Bioterrorism Nurse Consultant
Division of Acute Disease Epidemiology
Each January, South Carolina DHEC publishes lists of
health conditions that exclude children and child-care staff
from school attendance or out-of-home child-care settings.
The exclusion lists address three barriers to attendance:
• Symptoms of communicable disease,
• Diagnosis of communicable disease, and
• Exposure to or susceptibility to communicable
disease during an outbreak of an excludable
disease.
Symptoms of Communicable Disease or Severe Illness.
Children are excluded from school and child-care
attendance when they have:
• Diarrhea (Three or more loose stools in 24 hours,
or diarrhea with blood and/or mucous.)
• Vomiting (Two or more times in the previous 24
hours, unless determined to be non-
communicable.)
• Fever (oral 101º F or higher; axillary 100º F or
higher; rectal for infants 101º F or higher.)
• Rash associated with fever and/or behavioral
change.
• Symptoms of possibly severe illness such as
difficulty breathing, unusual lethargy or unusually
severe irritability.
For children in out-of-home child care, the list further
excludes for:
• Mouth sores associated with drooling, until
determined to be non-infectious;
• Persistent crying (when a symptom of illness);
• Illness that prevents the child from participating
comfortably in program activities;
• Illness that results in a greater need for care than
the staff can provide without compromising the
health and safety of other children;
For all of these symptoms, the exclusion lists specify
whether a parent-written or medical note is required to
return to school.
Diagnosis of Communicable Disease.  Children and child-
care staff are excluded when diagnosed with:
• Dermatological: Scabies, Pediculosis, Tinea
capitis, Tinea corporis, Impetigo.
• GI:  E. coli, Salmonella typhi, Shigellosis,
Giardiasis.
• HEENT:  Streptococcal pharyngitis, Purulent
conjunctivitis.
• Vaccine Preventable: Measles, Mumps, Rubella,
Congenital Rubella through 12 months of age
(see Childcare Exclusion List for details on
admission criteria for younger infants), Varicella,
Herpes Zoster, Hepatitis A, Pertussis.
• Other: TB, and conditions or illnesses that a
DHEC or a health care provider indicates warrant
exclusion.  This includes children determined to
be contributing to the transmission of illness in
the school or facility.
The exclusion lists specify the criteria (treatments and/or
laboratory results or symptom resolution) required to return
to school or out-of-home child care; most of these
diagnoses also require a medical note for re-admission.
Exclusion Associated with an Outbreak in the School or
Community.
• DHEC may require antibiotic prophylaxis for
contacts to Haemophilus influenzae type B (Hib),
N. meningitides, or B. pertussis.
• Non-immunized children, irrespective of reason
for not receiving vaccine, may be excluded when
exposed to Measles, Mumps, or Rubella, plus
Pertussis for children under age 7.
• DHEC may also opt to recommend exclusion for
exposure to other conditions.
FAQ on the Exclusion Lists:
1. Must children sent home with head lice be nit-free
before returning to school or childcare?  Although
thorough combing of the hair with a nit comb can help
eliminate remaining viable nits following pediculicidal
treatment, neither the Red Book nor S.C. DHEC mandates
that children be nit-free when returning to school or out-of-
home child care.  Some local school districts have “No-
Nit” policies, and children attending school in these districts
should be given information on manual nit removal.
2. Where is scarlet fever on the exclusion list?  Scarlet
fever, like a number of other illnesses, is not specifically
addressed in the exclusion lists.  However, exclusion is
required for fever, fever with rash, and (for child care) illness
that prevents the child from participating comfortably in
program activities.  Children should remain out of school
or child care until all of these symptoms are resolved.
3. Does an entire classroom need treatment for scabies
if more than one case occurs there?  This
recommendation appears in Infection Control in the
Childcare Center and Preschool.  The Red Book (2003)
and the CDC recommend treatment/prophylaxis for
individuals having prolonged close contact with the
infested person.  While this could apply to some or all of a
child’s contacts in an out-of-home child-care setting, it
might not apply to all children in a classroom or child-care
group.  The Division of Acute Disease Epidemiology does
not currently recommend prophylaxis/treatment for all
exposed children, due to the side effect profiles of many
commonly used scabicidal preparations.  Classroom-wide
prophylaxis may be considered on a case-by-case basis
for recalcitrant outbreaks.
4. Should diapered children be excluded for genital
herpes infection?  Children with mouth sores who cannot
control oral secretions are excluded from out-of-home
(Continued on Page 8)
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childcare until the lesions are determined to be non-
infectious.  This criterion does not apply to genital lesions.
Caregivers should use standard hygienic practices when
diapering children.
5. Must non-immunized children be excluded when there
is chickenpox in the school?  Non-immunized school
children must have a documented religious or medical
exemption from immunization.  Licensed physicians use
the DHEC form 1148 (South Carolina Certificate of
Immunization) to indicate medical exemptions to
immunization.  The South Carolina Certificate of Religious
exemption is available only from DHEC clinics.  DHEC
policy is for parents presenting with a religious exemption
to receive counseling regarding the possibility of exclusion
during outbreaks of vaccine-preventable diseases.
The 2006-2007 school and child-care exclusion lists do
not mandate exclusion for non-immunized children during
a Varicella outbreak.  As a disease control measure,
exclusion for one incubation period (21 days for Varicella)
has typically been used to protect both the susceptible
child and his/her contacts who may not have received full
immunity from immunization.  Because on-going
outbreaks may exclude susceptible children for multiple
incubation periods, DHEC Regional Public Health
Departments, in consultation with the Division of Acute
Disease Epidemiology, will offer outbreak-specific
consultation for schools and out-of-home child-care
providers.
6. Whom should I call for consultation on exclusion from
school or out-of-home childcare?  Questions may be
directed to Regional Disease Surveillance and Response
Coordinators (phone numbers are found on the Reportable
Disease poster and on the DHEC web site @ http://
w w w . s c d h e c . g o v / h e a l t h / d i s e a s e / d o c s /
reportable_conditions.pdf or from the Division of Acute
Disease Epidemiology: (803) 898-0861.
The school and child-care exclusion lists are available on
the DHEC Bureau of Disease Control’s Web site, at: http:/
www.scdhec.gov/health/disease/exclusion.htm.  The
2006-2007 school and child-care exclusion lists, revised
in January 2006, become effective July 1, 2006.
The School Exclusion List applies to most students in the
first through twelfth grades.  The Child-Care Exclusion
List applies to all children in out-of-home child care, to
children in 3-, 4-, or 5-year-old kindergarten, and to
medically fragile students in the first through twelfth
grades.  For the purposes of school exclusion, “medically
fragile students” are those with special health care needs
or developmental delays who require close assistance
with feeding or other personal hygiene activities by which
communicable illnesses may easily be spread.
Parent brochures, which can be printed on legal-sized
paper for distribution to families, are also found on the
Exclusion List Web site.
The Division of Acute Disease Epidemiology would
appreciate any feedback from health care providers on the
School or Child-Care Exclusion Lists.   Contact us at:
Exclusion@dhec.sc.gov.
(CIGUATERA FISH POISONING cont'd from Page 5)
(EXCLUSION LISTS cont'd from Page 7)
poisoning from fish caught off the coast of Texas 1 and
North Carolina 2.
The first symptom of Ciguatera fish poisoning from fish in
the Caribbean tends to be gastrointestinal syndrome,
consisting of nausea, vomiting, diarrhea, and abdominal
pain that begins two to 30 hours after a person eats the
fish. 1, 3, 4  It is often associated with cardiovascular
symptoms such as hypotension, bradycardia, arrhythmias,
or heart block. Then, over the first 24 hours, there may be
development of neurological symptoms such as profound
weakness, paresthesias, severe pruritus, tooth pain or
the feeling that teeth are loose, pain on urination, and
blurred vision. Hot-cold temperature reversal is
pathognomonic, although it is not always present.
Although complete recovery usually occurs within a few
weeks, neurological symptoms may last for months to
years, and symptoms may periodically recrudesce.
Although rare, ciguatera may cause death by respiratory
failure, circulatory collapse, or arrhythmias.
Currently, the CDC is performing surveillance for ciguatera
fish poisoning in recreational fishers off the coast of Texas.
They are also interested in documenting the spread of
fish containing ciguatoxin north along Atlantic coast.  All
suspected ciguatera fish poisoning cases, including those
thought to be from locally-caught fish, should be reported
to your local public health department. Please ask the
patient to save any remaining fish for testing.
Additional information about ciguatera fish poisoning can
be found at:
http://www.cdc.gov/nceh/ciguatera/
1. Villareal, T., G.E. Luber, and L. Backer.
2005. Surveillance for Ciguatera Fish Poisoning in
Recreational Fishers Utilizing Texas Gulf Coast Oil Rigs
(Poster presentation). Third Symposium on Harmful
Marine Algae in the U.S., Monterrey, CA, October 2005.
2. Morris, P.D., D.S. Campbell, and J.I. Freeman. 1990.
Ciguatera fish poisoning: an outbreak associated with
fish caught from North Carolina coastal waters. South
Medical Journal 83: 371-372.
3 .  Heymann, D. L. (ed.). 2004. Control of
Communicable Diseases Manual, 18th ed. American
Public Health Association, Washington, DC, p. 218-219.
4.  Fleming, L. E.  Ciguatera Fish Poisoning. http://
www.whoi.edu/redtide/illness/
ciguatera_fish_poisoning.html. Accessed 2/21/06.
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Varicella Disease - A Review And An
Update On
New Recommendations For Vaccination
Shirley Jankelovich, MD
Medical Epidemiologist – Immunization Division and
The Division of Acute Disease Epidemiology
Varicella-zoster virus (VZV) is a DNA virus and is a member
of the herpesvirus group.  VZV, as with all herpesviruses,
has the capacity to persist in the body after the primary
infection and reactive at a later time.  After initial exposure
to VZV, the infected person develops chickenpox.  When
VZV reactivates, it causes a disease called zoster
(shingles) that can occur many years after the primary
infection.
Pathogenesis
VZV enters through the respiratory tract and conjunctiva.
The virus is believed to replicate at the site of entry in the
nasopharynx and in regional lymph nodes. The virus
disseminates though the bloodstream (primary viremia)
four to six days after infection and infects multiple organs
and tissue, such as the liver, spleen, and sensory ganglia.
Further replication occurs in the viscera and the virus again
disseminates widely.  During this second stage of viremia,
VZV infects the skin and causes “chickenpox”.  Virus from
these pox are highly contagious.
After VZV infects the skin, it travels from the skin up the
sensory nerve to the dorsal root ganglia. It stays there in
an inactive form until some stimulus reactivates it.  Once
reactivated, it travels down the sensory nerve and causes
shingles (zoster).  There, the virus re-infects the
dermatome supplied by the sensory ganglia to produce
painful vesicles on the skin.
Varicella Disease
Acute varicella is generally mild and self-limited, but may
be associated with complications. The rash of varicella is
generalized, pruritic, and rapidly progresses from macules
to papules to vesicles to crusted lesions.  It usually appears
on scalp, then trunk, and then extremities.  Vesicles can
occur on mucous membranes, including the oropharynx,
respiratory tract, vagina, conjunctiva, and the cornea.  The
vesicles are usually one to four mm in diameter and are
superficial and delicate and contain clear fluid on a red
base (“dew drops on a rose petal”).  Successive crops
appear over several days, with lesions present in several
stages of development. For example, macular lesions may
be observed in the same area of skin as mature vesicles.
Healthy unvaccinated children usually have 200–500
lesions in two to four successive crops while vaccinated
children most often have less than 200 lesions.
Adults may have more severe disease and have a higher
incidence of complications. Children with cell-mediated
immunosuppression such as lymphoma, leukemia, and
HIV may develop a severe progressive form of
varicellacharacterized by high fever, extensive vesicular
eruption,  and high complication rates.
The incubation period of varicella is from 14 to 16 days
from exposure, with a range of 10 to 21 days. The
incubation period may be prolonged in
immunocompromised patients and those who have
received varicella zoster immune globulin.  For example,
the incubation period may be up to 28 days after varicella
zoster immune globulin.
Recurrent Varicella
Recovery from primary varicella infection usually results
in lifetime immunity.  However, recurrences of varicella-
like rash have been reported by 4 percent to 13 percent of
individuals who had previous varicella infection.  Risk
factors were young age (< 12 months) at first infection and
having a milder first infection.
Complications of Varicella Disease
Acute varicella is generally mild and self-limited but may
be associated with complications even in healthy children.
The most common complications of varicella are
secondary bacterial infections of skin lesions with
staphylococcus or streptococcus, dehydration, varicella or
bacterial pneumonia, central nervous system involvement
(aseptic meningitis, cerebellar ataxia, encephalitis and
Reye syndrome), severe dissemination with thousands
of lesions, and hemorrhagic varicella.
Persons who are at increased risk for complications of
varicella include healthy adults, persons with deficient cell-
mediated immunity (leukemia, lymphoma, steroid therapy,
HIV), newborns of mothers with rash onset within five days
before deliver to 48 hours after delivery, and infants born to
women infected with varicella during the first and second
trimesters of pregnancy.
The risk of complications from varicella varies with age.
Although complications are infrequent among healthy
children, they are much higher in persons older than 15
years of age and infants younger than 1 year of age.  Among
children 1–14 years of age, the fatality rate of varicella is
approximately 1 per 100,000 cases, while the rates among
persons 15–19 years and among adults 30–49 years of
age is 2.7 per 100,000 cases and 25.2 per 100,000 cases,
respectively. Adults account for only five percent of reported
cases of varicella, but account for approximately 35 percent
of mortality.
Complications Due to Neonatal Varicella
Neonates of mothers who develop varicella rash within
five days before delivery to 48 hours after delivery do not
receive protective transplacental antibodies from mother.
Severe varicella develops with a fatality rate of 30%.
Congenital Varicella Syndrome
Infants born to women infected with varicella during the
first two trimesters of pregnancy can have VZV transmitted
to them transplacentally.  The complications that are seen
include cicatricial cutaneous scarring of an extremity,
hypoplasia of an extremity, low birth weight, microcephaly,
Epi Notes             Page 9                       Spring 2006
(Continued on Page 10)
Digitized by South Carolina State Library
mental retardation, ocular anomalies, and neurological
abnormalities. The rate of congenital varicella syndrome
is 0.4 percent to 2.0 percent of infants born to women
infected with varicella during the first two trimesters of
pregnancy.
Transmission
Transmission occurs person-to person from infected
respiratory tract secretions or via airborne droplets.
Transmission may also occur through direct contact or
inhalation of aerosols from vesicular fluid of skin lesions
of acute varicella or zoster.
In unvaccinated persons, varicella is highly contagious.
The secondary attack rate among susceptible household
contacts is approximately 90 percent.  The period of
communicability in healthy persons with varicella is
approximately one to two days before onset of rash until
lesions have formed crusts.  In immunocompromised
patients the period of communicability is during the entire
period that new lesions are appearing.
In vaccinated persons, transmission of varicella from
breakthrough cases depends on number of lesions.  A
breakthrough infection with varicella is one that occurs
>42 days following varicella vaccination.  If a vaccinated
person with breakthrough varicella has >50 lesions,
transmission is similar to that of unvaccinated cases.
However, if <50 lesions occur, transmission is signi-
ficantly less.
Varicella Epidemiology Before and After Vaccine
(1995)
In the prevaccine era (before 1995), varicella was
endemic in the US.  It was mainly a childhood disease
with 50 percent infected by five years of age and 90
percent by 12 years of age.  The highest age-specific
incidence of varicella was among children one to four years
of age, who accounted for 39 percent of all cases. This
age distribution was probably a result of earlier exposure
to VZV in preschool and childcare settings. Children five to
nine years of age accounted for 38 percent of cases.  Adults
20 years of age and older accounted for only seven percent
of cases.  There were approximately 4 million infections
per year, 11,000 hospitalizations per year, and 100 deaths
per year.
The introduction of varicella vaccine in 1995 has resulted
in a continued significant decline in deaths,
hospitalizations, and ambulatory visits due to varicella as
the rate of vaccine coverage has increased.  By 2003, 85
percent of children in this age group were vaccinated and
a corresponding decrease in varicella deaths and
hospitalizations of approximately 90 percent in children
less than 10 years of age was seen.  Despite this success,
varicella cases and outbreaks continue to be reported.
Most of these cases are mild.  In 2004 and 2005, 32,868
and 26,532 cases of varicella, respectively, were reported
to CDC.  Many of these cases are due to breakthrough
varicella (see “Vaccine” below).
Laboratory Diagnosis of Varicella
The most rapid laboratory method for diagnosis of varicella
is polymerase chain reaction (PCR). The PCR test for
varicella is sensitive, specific, and rapid.  Another rapid
test is direct fluorescent antibody (DFA) method.  However,
this test is less sensitive than PCR and requires more
meticulous specimen collection and handling. The
laboratory diagnosis of varicella may also be made by
viral culture of vesicular fluid (offered at DHEC Bureau of
Laboratories).  Because the varicella-zoster virus is very
delicate, the specimen must be collected and transported
at the proper temperature with great care.  The results of
culture take several days.
Serology may be used to determine immune status or a
recent varicella infection.  In the latter case, a four-fold
increase in titer by any standard varicella serologic test
supports the occurrence of a recent infection.
Acceptable Evidence Of Varicella Immunity (New Criteria
As Of 2005)
As per ACIP, evidence of immunity to varicella includes any
of the following:
     1. Written documentation of age-appropriate
                vaccination.
     2. Born in the United States before 1966.
     3. History of varicella disease based on
healthcare provider diagnosis or self or
parental report of typical varicella disease for
non-U.S.-born persons born before 1966, and
all persons born during 1966–1997. For
persons reporting a history of atypical mild
disease, healthcare providers should seek
either:
a. An epidemiologic link to a typical varicella
case (e.g., case occurred in the context
of an outbreak or patient had household
exposure in the previous 3 weeks), or
b. Evidence of laboratory confirmation, if it
was performed at the time of acute
disease.  When such documentation is
lacking, persons should not be
considered as having a valid history of
disease because other diseases may
mimic mild atypical varicella. For persons
born during or after 1998, history of
disease is no longer considered as
evidence of immunity, unless the illness
was laboratory confirmed.
4. History of herpes zoster based on healthcare
provider diagnosis.
5. Laboratory evidence of immunity or laboratory
confirmation of disease.
Varicella Vaccine
Varicella zoster vaccine is a live attenuated viral vaccine
and is available as varicella vaccine alone or in
combination as measles-mumps-rubella and varicella
(MMRV) vaccine (ProQuad).
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Varicella vaccine produces antibody in 97 percent of
children 12 months of age to 12 years of age after one
dose of vaccine and >90 percent maintain antibody for >6
years.  The vaccine is 70 percent to 90 percent effective
against infection but is much more effective in preventing
severe disease.  Breakthrough varicella infections occur
in vaccinated persons at a rate of approximately one
percent to four percent per year.  Risk of breakthrough
varicella is increased if:  1) varicella vaccine was
administered before 15 months of age, 2) there was a
rash after vaccination, 3) varicella vaccine was
administered within < 30 days of receiving MMR or, 4) the
vaccine was stored at improper temperature.
2006 Recommendations for Varicella Immunization for
Children and Adults
A single dose of varicella vaccine continues to be
recommended for children at 12-18 months of age.  The
three new 2006 recommendations are: 1) all susceptible
children <13 years old should receive one dose; 2) all
susceptible children >13 years old and adults should
receive two doses; and 3) during an outbreak, all persons
who have received the first dose should receive a second
dose if resources permit.  The new MMRV vaccine may be
used for varicella vaccination if MMR is also indicated at
that time.
Prophylaxis After Exposure to Varicella
There are several approaches to postexposure prophylaxis
against varicella.  These are immune globulin, varicella
immune globulin, varicella vaccine, and antivirals active
against varicella virus.  Although VZIG (varicella zoster
immune globulin) is no longer available, there are two
alternatives.  These are immune globulin and an
investigational agent - varicella zoster immune globulin
(VariZig) - that is manufactured in Canada.  VariZig can be
obtained from its distributor after contacting the DHEC
Immunization Division.  VariZig or immune globulin is
recommended for postexposure prophylaxis of varicella
for the following persons:
     1. Immunocompromised patients.
     2. Neonates whose mothers develop signs and
symptoms of varicella around the time of delivery
(five days before to two days after).
     3. Premature infants 28 weeks or greater who are
exposed during the neonatal period whose
mothersdo not have evidence of immunity
     4. Premature infants who are less than 28 weeks’
gestation or who weigh less than 1,000 grams
at birth and who are exposed during the
neonatal period, regardless of maternal history
of varicella.
     5. Pregnant women.
Varicella vaccine may also be used for postexposure
prophylaxis in susceptible persons in whom the vaccine
is not contraindicated.  The vaccine is 70 percent to100
percent effective in preventing infection if given within 72
hours to five days of exposure.
Acyclovir may be given for prophylaxis in special
circumstances but should be done only with a physician
consultation.
Childcare Exclusion Criteria
Children attending child care or school or employees in
out-of-home child care settings with either chickenpox or
shingles must be excluded from the child care/school
setting until all lesions have dried and crusted.  Children
who have not received varicella vaccine may also be
excluded if they have been exposed to varicella (see
Outbreak Control).
Outbreak Control
Varicella outbreaks in some settings (e.g., child care
facilities, schools, institutions) can last three to six months
and may involve children who have been appropriately
immunized with varicella vaccine. Non-immunized day care
or school children who are exposed to varicella but who
have not received varicella vaccine may be excluded on a
case-by-case basis.  Varicella vaccination of susceptible
persons has been used successfully for outbreak
prevention and control.  Therefore, unimmunized children
and all other susceptible persons, including adolescents
and adults, should be encouraged to receive varicella
vaccine. Furthermore, during an outbreak, persons who
have received one dose of varicella vaccine should,
resources permitting, receive a second dose, provided
the appropriate vaccination interval has elapsed since the
first dose (three months for persons aged 12 months to
12 years and at least four weeks for persons aged e”13
years).
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Year-to-Date Summary of Selected Reportable Conditions*
*This report does not include reportable STD conditions.
** Not reportable for 2006
 2005 Year Total January 1, 2006 - March 1, 2006 January 1, 2005 - March 1, 2005 
Condition Confirmed  Probable 
Grand 
Total Confirmed  Probable 
Grand 
Total Confirmed  Probable 
Grand 
Total 
Cyclosporiasis 3   3 1   1       
Ehrlichiosis- human granulocytic 6 3 9      3   3
Ehrlichiosis- human monocytic 1 3 4      1 3 4
Ehrlichiosis- human- other&unspec   4 4  1 1       
Encephalitis- Eastern equine 1   1            
Encephalitis- West Nile 4   4            
Enterohem. E.coli O157:H7 9   9 2   2       
Enterohem.E.coli shigatox+- ?serogrp 3 1 4            
Enterohem.E.coli- shigatox+- non-O157 1   1            
Giardiasis 106 2 108 19   19 23 2 25
Group A Streptococcus- invasive 38   38 21   21 8   8
Group B Streptococcus- invasive 27   27 4   4 7   7
Haemophilus influenzae- invasive 35   35 11   11 2   2
Hemolytic uremic synd- postdiarrheal 1   1      1   1
Hepatitis A- acute 40   40 7   7 5   5
Hepatitis B- acute 142 31 173 14 4 18 23 11 34
Hepatitis B virus infection- chronic 611 82 693 85 16 101 125 17 142
Hepatitis C- acute 2 4 6        1 1
Hepatitis C Virus Infection- past or present 2505 2579 5084 322 320 642 432 420 852
Hepatitis E- acute       1   1       
HTLV-I infection** 2   2            
HTLV-II infection** 3   3            
Influenza- human isolates 52   52 12   12 27   27
Kawasaki disease 3 1 4            
Legionellosis 15 2 17 1   1 1   1
Listeriosis 15 1 16            
Lyme disease 17 7 24 2   2 7 2 9
Malaria 11   11 2   2 1   1
Mumps 1   1            
Neisseria meningitidis- invasive (Mening. disease) 15 1 16 6   6 6 1 7
Pertussis 368 40 408 25 4 29 85 9 94
Q fever   1 1            
Rocky Mountain spotted fever 20 61 81 1 2 3 1 3 4
Rotavirus 1   1            
Salmonellosis 1235 247 1482 66 1 67 109 1 110
Scombroid fish poisoning 2   2            
Shigellosis 102 4 106 28   28 18   18
Strep pneumoniae- invasive 196 2 198 59   59 47 1 48
Streptococcal disease- invasive- other 23   23 7   7 8   8
Toxic-shock syndrome- staphylococcal       1   1       
Tularemia   1 1            
Vancomycin-Resistant Enterococcus** 1516 5 1521    261 2 263
Varicella (Chickenpox) 259 396 655 161 81 242 59 84 143
Vibrio parahaemolyticus 1   1 1   1       
Vibrio spp.- non-toxigenic- other or unspecified 6   6  1 1       
West Nile Fever 1   1 1   1       
Yersiniosis 2   2 2   2       
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